In this free webinar, attendees will gain insights into the role of hybrid liquid chromatography-mass spectrometry (LC-MS/MS) as an increasingly valuable tool for the bioanalysis of antibody-drug conjugates (ADCs) to enhance the drug development process. Attendees will also hear about the bioanalytical challenges associated with ADCs, the different types of modalities that are classified as ADCs and different strategies for developing "ADC assays."

TORONTO, May 6, 2024 /PRNewswire-PRWeb/ -- Recently, the role of hybrid liquid chromatography-mass spectrometry (LC-MS/MS) in the analysis of antibody-drug conjugates has increased due to the complexity and number of bioanalytical assays needed to support this modality in the drug development process. Antibody-drug conjugates tend to consist of a toxic small molecule payload attached via a linker to an antibody. The application of these drugs had mainly been in oncology where their mode of action is for the antibody to attach at the desired target site with subsequent release of the small molecule to combat tumor cells.

Recently, a much wider application or use of "ADCs" to other modalities such as antibody-peptide conjugates, antibody-RNA conjugates (ARCs) or even other more complicated multi-functional entities has been reported. Traditionally, LC-MS/MS has mainly been applied to the quantitation of the small molecule payload or the linker moiety. Ligand-binding assays are highly successful for the quantitation of the total antibody and sometimes may be suitable for the quantification of intact antibody-drug conjugates.

More recently, a trend of performing all analyses on LC-MS/MS has been observed. Hybrid LC-MS/MS can easily be used to monitor both the total antibody as well as the antibody-drug conjugates. Depending on the type of conjugation and linker used (site-specific vs Cys or Lys conjugation and cleavable vs non-cleavable) and what reagents are available, hybrid LC-MS/MS offers several strategies or advantages to monitor the various constituent parts of antibody-drug conjugates.

This also gives scientists flexibility for the quantitation of antibody-drug conjugates. In many cases, ligand binding or hybrid LC-MS/MS can be applicable. However, poor reagents or limited availability of reagents can limit the immediate application of ligand binding. The ability to approach the analysis from different angles to gain multiple insights into the analyte can increasingly nudge the decision towards the use of LC-MS/MS.

In many preclinical cases, "generic" methods that make the method development and analysis much quicker and more cost-effective are used. At the very least, the availability of hybrid LC-MS/MS as an alternative technology greatly increases the chances of success in the bioanalysis of antibody-drug conjugates.

Hybrid LC-MS/MS is proving to be an increasingly valuable tool for delivering answers about complex analytes such as antibody-drug conjugates to enhance the drug development process. Register for this webinar today to get an overview of the bioanalysis of antibody-drug conjugates.

Join featured speaker Dawn Dufield, Scientific Officer, Mass Spectrometry, KCAS Bio, for the live webinar on Tuesday, May 21, 2024, at 1pm EDT (10am PDT).

For more information, or to register for this event, visit Hybrid LC-MS/MS Technology Becoming the New Norm in the Bioanalysis of Antibody-Drug Conjugates – Examples and Case Studies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/

Media Contact

Ayesha Rashid, Xtalks, +1 (416) 977-6555 x272, arashid@xtalks.com, https://xtalks.com 

View original content to download multimedia:https://www.prweb.com/releases/hybrid-lc-msms-technology-becoming-the-new-norm-in-the-bioanalysis-of-antibody-drug-conjugates--examples-and-case-studies-upcoming-webinar-hosted-by-xtalks-302135729.html

SOURCE Xtalks